Unknown

Dataset Information

0

Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer?

ABSTRACT:

SUBMITTER: Dempke WC 

PROVIDER: S-EPMC5099520 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer?

Dempke Wolfram C M WC   Fenchel Klaus K  

Translational lung cancer research 20161001 5

Similar Datasets

Unknown Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expression.
| S-EPMC9207363 | biostudies-literature
Unknown Concomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non-Small-Cell Lung Cancer.
| S-EPMC12423871 | biostudies-literature
Unknown Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy-free, first-line treatment for PD-L1-positive non-small cell lung cancer.
| S-EPMC7240850 | biostudies-literature
Unknown First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
| S-EPMC8645705 | biostudies-literature
Unknown First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
| S-EPMC7734005 | biostudies-literature
Unknown First-line treatment of advanced ALK-positive non-small-cell lung cancer.
| S-EPMC5217519 | biostudies-literature
Unknown Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small Cell Lung Cancer.
| S-EPMC8342563 | biostudies-literature
Unknown Is first-line pembrolizumab appropriate for all patients with metastatic non-squamous histology non-small cell lung cancer patients?
| S-EPMC6987360 | biostudies-literature
Unknown Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29)
| S-EPMC9989798 | biostudies-literature
Unknown Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer.
| S-EPMC9133943 | biostudies-literature